Skip to main content
Fig. 4 | Translational Neurodegeneration

Fig. 4

From: Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Fig. 4

InRapa reduces APP expression levels, APP metabolites and APP processing. (a 1–8) Representative immunofluorescent images showing APP/Aβ (B-4) signal in the CA3 region of the hippocampus from euploid mice treated with Veh and InRapa (a.1–4), and Ts65Dn mice treated with Veh and InRapa (A.5–8). DAPI (blue) was used to identify cell nuclei. Scale bar represent 20 μm. (b) Quantification of fluorescence signal. (c) Representative WB showing total hippocampal levels of APP (full and B-4), BACE1, Aβ oligomers (25 and 50 kDa) and β and α CTF. (d) Quantification of panel C showing APP, β and α CTF and BACE1 levels. (e) Quantification of panel C showing BACE1 levels. (f) Quantification of panel C showing Aβ oligomers (25 and 50 kDa) levels. (g) Quantification of mRNA levels of APP analyzed by RT-PCR analysis. Densitometry values shown in the bar graph are the mean of 8 (WB) and 6 (RT-PCR) samples per each group, normalized per total load and given as percentage of Eu Veh, set as 100%

Back to article page
\